From Content Scramble to Streamlined Success: Demystifying Modular Content in Life Sciences

 

Modular content is the latest buzz in the life sciences industry, offering a strategic way to streamline content creation and management. With promises of increased efficiency and personalized outreach, many organizations are eager to jump on the bandwagon. But is it truly worth the effort?

What exactly is modular content, and how can life science organizations leverage it effectively?

Welcome to “Amend & Progress,” Vodori’s podcast dedicated to exploring promotional material review processes. In this episode, Annalise Ludtke hosts a discussion on modular content with Alana Goodman, Program and Operations Lead at Decisive Consulting, and Stephanie Taubin, founder and CEO at Taubin Collaborative Solutions. They explore the nuances of modular content, its challenges, and strategies for successful adoption in the life sciences industry.

Main Points of Discussion

  • Understanding Modular Content: Alana and Stephanie define modular content and emphasize its strategic nature rather than just a capability, highlighting the importance of people, processes, and technology.
  • Challenges in Implementation: The discussion covers the regulatory and operational hurdles that organizations face, emphasizing the need for a solid foundation and trust within teams.
  • Steps to Successful Adoption: Practical advice on building a robust digital asset management system and the importance of change readiness before diving into modular content.

Alana Goodman is the Program and Operations Lead at Decisive Consulting, with over 13 years of experience in content operations and industry consulting. She has been involved in ten product launches across various therapies and organizations. Alana is passionate about precision marketing and the impact of content in life sciences.

Stephanie Taubin is the founder and CEO of Taubin Collaborative Solutions. With a background in the ad agency world and in-house pharmaceutical operations, Stephanie focuses on operationalizing creative teams and driving efficiency through digital asset management systems. She brings extensive experience in consulting and partnering with industry experts to help clients make informed decisions.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…